Antimicrobial Agents and Chemotherapy, volume 60, issue 1, pages 6-13

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Laurent Detalle ¹

Thomas Stöhr ¹

Concepción Palomo ²

Pedro A. Piedra ^{3, 4}

Brian E. Gilbert ³

Vicente Más ²

Andrena Millar ⁵

Ultan F Power ⁵

Catelijne Stortelers ¹

Koen Allosery ¹

Jose A. Melero ²

Erik Depla ¹

Hide authors affiliations Show authors affiliations: 5 affiliations

Ablynx nv, Zwijnaarde, Belgium |

Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain |

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA |

⁴

Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA |

⁵

Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom |

Publication type: Journal Article

Publication date: 2016-01-09

American Society for Microbiology

Journal: Antimicrobial Agents and Chemotherapy

Quartile SCImago

Quartile WOS

Impact factor: 4.9

ISSN: 00664804, 10986596

DOI: 10.1128/aac.01802-15

Copy DOI

Pharmacology

Infectious Diseases

Pharmacology (medical)

Abstract

ABSTRACT

Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.

By date By citations

Top-30

Citations by journals

	2 4 6 8 10 12
Frontiers in Immunology	Frontiers in Immunology, 11, 4.93% Frontiers in Immunology 11 publications, 4.93%
Scientific Reports	Scientific Reports, 8, 3.59% Scientific Reports 8 publications, 3.59%
Antimicrobial Agents and Chemotherapy	Antimicrobial Agents and Chemotherapy, 7, 3.14% Antimicrobial Agents and Chemotherapy 7 publications, 3.14%
Nature Communications	Nature Communications, 6, 2.69% Nature Communications 6 publications, 2.69%
Viruses	Viruses, 5, 2.24% Viruses 5 publications, 2.24%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 5, 2.24% International Journal of Molecular Sciences 5 publications, 2.24%
Journal of Virology	Journal of Virology, 4, 1.79% Journal of Virology 4 publications, 1.79%
Pharmacology and Therapeutics	Pharmacology and Therapeutics, 4, 1.79% Pharmacology and Therapeutics 4 publications, 1.79%
Frontiers in Microbiology	Frontiers in Microbiology, 3, 1.35% Frontiers in Microbiology 3 publications, 1.35%
Journal of Nanobiotechnology	Journal of Nanobiotechnology, 3, 1.35% Journal of Nanobiotechnology 3 publications, 1.35%
Expert Opinion on Pharmacotherapy	Expert Opinion on Pharmacotherapy, 3, 1.35% Expert Opinion on Pharmacotherapy 3 publications, 1.35%
Antiviral Research	Antiviral Research, 3, 1.35% Antiviral Research 3 publications, 1.35%
mAbs	mAbs, 3, 1.35% mAbs 3 publications, 1.35%
Science	Science, 3, 1.35% Science 3 publications, 1.35%
Antibodies	Antibodies, 2, 0.9% Antibodies 2 publications, 0.9%
Microorganisms	Microorganisms, 2, 0.9% Microorganisms 2 publications, 0.9%
Frontiers in Pharmacology	Frontiers in Pharmacology, 2, 0.9% Frontiers in Pharmacology 2 publications, 0.9%
Journal of Biological Chemistry	Journal of Biological Chemistry, 2, 0.9% Journal of Biological Chemistry 2 publications, 0.9%
Cell Reports	Cell Reports, 2, 0.9% Cell Reports 2 publications, 0.9%
iScience	iScience, 2, 0.9% iScience 2 publications, 0.9%
International Journal of Biological Macromolecules	International Journal of Biological Macromolecules, 2, 0.9% International Journal of Biological Macromolecules 2 publications, 0.9%
Advanced Drug Delivery Reviews	Advanced Drug Delivery Reviews, 2, 0.9% Advanced Drug Delivery Reviews 2 publications, 0.9%
Vaccine	Vaccine, 2, 0.9% Vaccine 2 publications, 0.9%
Cell	Cell, 2, 0.9% Cell 2 publications, 0.9%
International Journal of Pharmaceutics	International Journal of Pharmaceutics, 2, 0.9% International Journal of Pharmaceutics 2 publications, 0.9%
Biochimica et Biophysica Acta - General Subjects	Biochimica et Biophysica Acta - General Subjects, 2, 0.9% Biochimica et Biophysica Acta - General Subjects 2 publications, 0.9%
Advanced Therapeutics	Advanced Therapeutics, 2, 0.9% Advanced Therapeutics 2 publications, 0.9%
Advances in Experimental Medicine and Biology	Advances in Experimental Medicine and Biology, 2, 0.9% Advances in Experimental Medicine and Biology 2 publications, 0.9%
Expert Opinion on Investigational Drugs	Expert Opinion on Investigational Drugs, 2, 0.9% Expert Opinion on Investigational Drugs 2 publications, 0.9%
	2 4 6 8 10 12

Citations by publishers

	5 10 15 20 25 30 35 40 45 50
Elsevier	Elsevier, 49, 21.97% Elsevier 49 publications, 21.97%
Springer Nature	Springer Nature, 45, 20.18% Springer Nature 45 publications, 20.18%
Multidisciplinary Digital Publishing Institute (MDPI)	Multidisciplinary Digital Publishing Institute (MDPI), 19, 8.52% Multidisciplinary Digital Publishing Institute (MDPI) 19 publications, 8.52%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 19, 8.52% Cold Spring Harbor Laboratory 19 publications, 8.52%
Taylor & Francis	Taylor & Francis, 18, 8.07% Taylor & Francis 18 publications, 8.07%
Frontiers Media S.A.	Frontiers Media S.A., 18, 8.07% Frontiers Media S.A. 18 publications, 8.07%
American Society for Microbiology	American Society for Microbiology, 12, 5.38% American Society for Microbiology 12 publications, 5.38%
Wiley	Wiley, 8, 3.59% Wiley 8 publications, 3.59%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 4, 1.79% American Association for the Advancement of Science (AAAS) 4 publications, 1.79%
SAGE	SAGE, 2, 0.9% SAGE 2 publications, 0.9%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 2, 0.9% Public Library of Science (PLoS) 2 publications, 0.9%
Oxford University Press	Oxford University Press, 2, 0.9% Oxford University Press 2 publications, 0.9%
American Physiological Society	American Physiological Society, 2, 0.9% American Physiological Society 2 publications, 0.9%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 2, 0.9% Proceedings of the National Academy of Sciences (PNAS) 2 publications, 0.9%
The American Association of Immunologists	The American Association of Immunologists, 1, 0.45% The American Association of Immunologists 1 publication, 0.45%
Bentham Science	Bentham Science, 1, 0.45% Bentham Science 1 publication, 0.45%
Future Medicine	Future Medicine, 1, 0.45% Future Medicine 1 publication, 0.45%
Microbiology Society	Microbiology Society, 1, 0.45% Microbiology Society 1 publication, 0.45%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 1, 0.45% American Society for Biochemistry and Molecular Biology 1 publication, 0.45%
KeAi Communications Co.	KeAi Communications Co., 1, 0.45% KeAi Communications Co. 1 publication, 0.45%
American Chemical Society (ACS)	American Chemical Society (ACS), 1, 0.45% American Chemical Society (ACS) 1 publication, 0.45%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 1, 0.45% Royal Society of Chemistry (RSC) 1 publication, 0.45%
Pleiades Publishing	Pleiades Publishing, 1, 0.45% Pleiades Publishing 1 publication, 0.45%
Publishing House OKI	Publishing House OKI, 1, 0.45% Publishing House OKI 1 publication, 0.45%
eLife Sciences Publications	eLife Sciences Publications, 1, 0.45% eLife Sciences Publications 1 publication, 0.45%
Annual Reviews	Annual Reviews, 1, 0.45% Annual Reviews 1 publication, 0.45%
Saint Petersburg Pasteur Institute	Saint Petersburg Pasteur Institute, 1, 0.45% Saint Petersburg Pasteur Institute 1 publication, 0.45%
Spandidos Publications	Spandidos Publications, 1, 0.45% Spandidos Publications 1 publication, 0.45%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 0.45% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 0.45%
	5 10 15 20 25 30 35 40 45 50

We do not take into account publications without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2016,2017,2018,2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0,0,0,0],"codes":[0,0,0,0,0,0,0,0,0],"imageUrls":["","","","","","","","",""],"datasets":[{"label":"Citations number","data":[4,22,21,13,37,34,36,31,25],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["1.79","9.87","9.42","5.83","16.59","15.25","16.14","13.9","11.21"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Frontiers in Immunology","Scientific Reports","Antimicrobial Agents and Chemotherapy","Nature Communications","Viruses","International Journal of Molecular Sciences","Journal of Virology","Pharmacology and Therapeutics","Frontiers in Microbiology","Journal of Nanobiotechnology","Expert Opinion on Pharmacotherapy","Antiviral Research","mAbs","Science","Antibodies","Microorganisms","Frontiers in Pharmacology","Journal of Biological Chemistry","Cell Reports","iScience","International Journal of Biological Macromolecules","Advanced Drug Delivery Reviews","Vaccine","Cell","International Journal of Pharmaceutics","Biochimica et Biophysica Acta - General Subjects","Advanced Therapeutics","Advances in Experimental Medicine and Biology","Expert Opinion on Investigational Drugs"],"ids":[1699,13767,17567,3231,2455,14627,19580,22929,24403,11794,23046,22274,9244,7711,25824,6197,9788,19451,9130,6073,23035,12266,8548,16552,3305,5266,25457,17590,1879],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/OuA6WPZekwEiUM99mP2pSqj4yHPxHezM6xgLhAjO_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp"],"datasets":[{"label":"","data":[11,8,7,6,5,5,4,4,3,3,3,3,3,3,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[4.93,3.59,3.14,2.69,2.24,2.24,1.79,1.79,1.35,1.35,1.35,1.35,1.35,1.35,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9,0.9],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Elsevier","Springer Nature","Multidisciplinary Digital Publishing Institute (MDPI)","Cold Spring Harbor Laboratory","Taylor & Francis","Frontiers Media S.A.","American Society for Microbiology","Wiley","American Association for the Advancement of Science (AAAS)","SAGE","Public Library of Science (PLoS)","Oxford University Press","American Physiological Society","Proceedings of the National Academy of Sciences (PNAS)","The American Association of Immunologists","Bentham Science","Future Medicine","Microbiology Society","American Society for Biochemistry and Molecular Biology","KeAi Communications Co.","American Chemical Society (ACS)","Royal Society of Chemistry (RSC)","Pleiades Publishing","Publishing House OKI","eLife Sciences Publications","Annual Reviews","Saint Petersburg Pasteur Institute","Spandidos Publications","Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii"],"ids":[17,8,202,6909,18,208,142,11,189,31,344,19,166,162,7871,39,6949,827,2090,326,40,123,101,9233,6627,6941,3515,1097,9422],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/hg4jJjT8wVGtHstBCc0zk465Mg9pLx3G4odCDOqE_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/eZQGZ1aBN8Xm8Yr5YG7nBeNQtWLPrca5SfDreLbq_medium.webp","\/storage\/images\/resized\/mxFdPe9qujsfvfYfcN0QOclAiYORFb0xrRlwV8gs_medium.webp","\/storage\/images\/resized\/Teo7jjEEA71rw8mjlFC8lDbYotZhhtZbL0J9gPs2_medium.webp","\/storage\/images\/resized\/doUaFUZdxUEQjLi1TwZjGHi8HXYNWWSk04dSC6Xh_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/RlMKyKHh4Q2iTSKF38VHwIFW4f6Ke5ChRSXbQHkq_medium.webp","\/storage\/images\/resized\/OuA6WPZekwEiUM99mP2pSqj4yHPxHezM6xgLhAjO_medium.webp","\/storage\/images\/resized\/jeWDR7NTA9Ab5MVz8Uqjl2RPCndzFjSyl0FaRAHg_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp","\/storage\/images\/resized\/0pyMnw6hqXp4LxgRirQNJzhuW46UNQvBNr64G5dP_medium.webp","\/storage\/images\/resized\/eIZgkq1MRZyJ3hBkdupnUUv7wgB6zCl9D99SlPN5_medium.webp","\/storage\/images\/resized\/A7oGMwx1m3fFJlKJvQUVra8h0itmEa7JZW0q3Q0b_medium.webp","","\/storage\/images\/resized\/8zKfOwdd5XirYzTQfqwp7U8IEQc8ckIOjyYQSBkk_medium.webp","\/storage\/images\/resized\/9Mus3KG1Tkd7Bwaurt8H3RwWh0CxRlGoO6ng9UK1_medium.webp"],"datasets":[{"label":"","data":[49,45,19,19,18,18,12,8,4,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[21.97,20.18,8.52,8.52,8.07,8.07,5.38,3.59,1.79,0.9,0.9,0.9,0.9,0.9,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45,0.45],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartiles":{"type":"bar","data":{"show":true,"labels":[2016,2017,2018,2019,2020,2021,2022,2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[0,0,0,0,3,1,0,0,0],"percentage":["0","0","0","0","1.35","0.45","0","0","0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[0,1,0,0,1,3,0,3,0],"percentage":["0","0.45","0","0","0.45","1.35","0","1.35","0"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[0,1,2,2,2,4,2,4,3],"percentage":["0","0.45","0.9","0.9","0.9","1.79","0.9","1.79","1.35"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[3,18,18,9,21,20,27,19,21],"percentage":["1.35","8.07","8.07","4.04","9.42","8.97","12.11","8.52","9.42"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[1,2,1,2,10,6,7,5,1],"percentage":["0.45","0.9","0.45","0.9","4.48","2.69","3.14","2.24","0.45"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by SCImago per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartilesWs":{"type":"bar","data":{"show":true,"labels":[2016,2017,2018,2019,2020,2021,2022,2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[0,0,1,1,2,0,0,1,0],"percentage":["0","0","0.45","0.45","0.9","0","0","0.45","0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[0,0,0,0,2,2,0,3,0],"percentage":["0","0","0","0","0.9","0.9","0","1.35","0"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[1,4,10,3,3,12,8,6,8],"percentage":["0.45","1.79","4.48","1.35","1.35","5.38","3.59","2.69","3.59"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[2,14,7,6,19,11,21,15,16],"percentage":["0.9","6.28","3.14","2.69","8.52","4.93","9.42","6.73","7.17"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[1,4,3,3,11,9,7,6,1],"percentage":["0.45","1.79","1.35","1.35","4.93","4.04","3.14","2.69","0.45"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by WoS per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Detalle L. et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection // Antimicrobial Agents and Chemotherapy. 2016. Vol. 60. No. 1. pp. 6-13.

GOST all authors (up to 50) Copy

Detalle L., Stöhr T., Palomo C., Piedra P. A., Gilbert B. E., Más V., Millar A., Power U. F., Stortelers C., Allosery K., Melero J. A., Depla E. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection // Antimicrobial Agents and Chemotherapy. 2016. Vol. 60. No. 1. pp. 6-13.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1128/aac.01802-15

UR - https://doi.org/10.1128/aac.01802-15

TI - Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

T2 - Antimicrobial Agents and Chemotherapy

AU - Detalle, Laurent

AU - Stöhr, Thomas

AU - Palomo, Concepción

AU - Piedra, Pedro A.

AU - Gilbert, Brian E.

AU - Más, Vicente

AU - Millar, Andrena

AU - Power, Ultan F

AU - Stortelers, Catelijne

AU - Allosery, Koen

AU - Melero, Jose A.

AU - Depla, Erik

PY - 2016

DA - 2016/01/09 00:00:00

PB - American Society for Microbiology

SP - 6-13

IS - 1

VL - 60

SN - 0066-4804

SN - 1098-6596

ER -

BibTex |

Cite this

BibTex Copy

@article{2016_Detalle,

author = {Laurent Detalle and Thomas Stöhr and Concepción Palomo and Pedro A. Piedra and Brian E. Gilbert and Vicente Más and Andrena Millar and Ultan F Power and Catelijne Stortelers and Koen Allosery and Jose A. Melero and Erik Depla},

title = {Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection},

journal = {Antimicrobial Agents and Chemotherapy},

year = {2016},

volume = {60},

publisher = {American Society for Microbiology},

month = {jan},

url = {https://doi.org/10.1128/aac.01802-15},

number = {1},

pages = {6--13},

doi = {10.1128/aac.01802-15}

}

MLA

Cite this

MLA Copy

Detalle, Laurent, et al. “Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.” Antimicrobial Agents and Chemotherapy, vol. 60, no. 1, Jan. 2016, pp. 6-13. https://doi.org/10.1128/aac.01802-15.

Found error?

Publisher

American Society for Microbiology

Journal

Antimicrobial Agents and Chemotherapy

Quartile SCImago

Quartile WOS

Impact factor

4.9

ISSN

00664804 (Print)
10986596 (Electronic)